Tags » William Ackman

"Our Sick Drug Business": Congress Writes Laws To Enrich Drug Companies At The Expense Of American Consumers

Sometimes the road to hell is paved with bad intentions. A company adopts a business model so twisted that justice must come clanking down on its executives and bankrollers. 585 more words


Valeant Pharmaceuticals faces tough choices in asset sales: Retire debt or give up cash flow

NEW YORK — As Valeant Pharmaceuticals considers a multi-billion-dollar auction to pare down US$30 billion in debt, its challenge will be choosing which assets to sell without compromising any of its key businesses, analysts and investment bankers said. 785 more words

Market Moves